Core Viewpoint - The company has signed a technical development cooperation contract with Shanghai Lekuang Huilin Pharmaceutical Technology Co., Ltd. for the joint development of the STC007 injection project, with a total milestone payment of 200 million yuan (including tax) [1] Group 1 - The collaboration aims to accelerate the commercialization process of the STC007 injection, providing more treatment options for clinical needs [1] - STC007 injection is primarily used for the treatment of moderate to severe pain following abdominal surgery and is currently in the Phase III clinical trial stage [1] - The execution of the contract is expected to have a positive impact on the company's current and future operating performance [1]